{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "ORPHAN DRUG|Designated/Withdrawn" in comments (approximate match)
Status:
Designated
Source:
FDA ORPHAN DRUG:46990
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Designated
Source:
FDA ORPHAN DRUG:386212
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA125738
(2023)
Source URL:
First approved in 2023
Source:
BLA125738
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA125703
(2020)
Source URL:
First approved in 2020
Source:
BLA125703
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT00255827: Phase 1/Phase 2 Interventional Completed Pancreatic Cancer
(2005)
Source URL:
Class:
G1 SPECIFIED SUBSTANCE
Status:
US Previously Marketed
Source:
SURFAXIN by LEES PHARM HK
(2012)
Source URL:
First approved in 2012
Source:
SURFAXIN by LEES PHARM HK
Source URL:
Class:
G1 SPECIFIED SUBSTANCE
Status:
Investigational
Source:
NCT01608711: Phase 2 Interventional Completed Pancreatic Cancer
(2012)
Source URL:
Class:
CONCEPT
Status:
Investigational
Source:
NCT00796055: Phase 1 Interventional Terminated Cancer
(2009)
Source URL:
Class:
CONCEPT
Status:
Investigational
Source:
NCT02674763: Phase 1 Interventional Completed Acute Myeloid Leukemia
(2016)
Source URL:
Class:
CONCEPT
Status:
Investigational
Source:
NCT03013998: Phase 1/Phase 2 Interventional Recruiting Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
(2016)
Source URL:
Class:
CONCEPT